Next, we analyzed CDK12 protein levels using a TMA containing 150 PCa specimens by immunohistochemical analysis and found that CDK12 protein was expressed at significantly higher levels in PCa tissues (Fig. 1E, F), indicating the feasibility of CDK12 as a target for PCa therapy. The gene discussed is CDK12; the disease is posterior cortical atrophy.